Fulgent Genetics - FLGT Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FLGT shares.
View FLGT analyst ratings or view top-rated stocks.

3 brokers have issued 1-year target prices for Fulgent Genetics' shares. Their FLGT share price forecasts range from $35.00 to $45.00. On average, they anticipate the company's share price to reach $41.67 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.

Fulgent Genetics' stock was trading at $29.78 at the start of the year. Since then, FLGT stock has increased by 1.2% and is now trading at $30.15.
View the best growth stocks for 2023 here.

Fulgent Genetics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 908,500 shares, an increase of 5.9% from the February 13th total of 857,800 shares. Based on an average trading volume of 239,200 shares, the short-interest ratio is currently 3.8 days. Currently, 4.9% of the company's shares are short sold.
View Fulgent Genetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our FLGT earnings forecast.

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.07. The company earned $67.70 million during the quarter, compared to analysts' expectations of $59.44 million. Fulgent Genetics had a trailing twelve-month return on equity of 11.93% and a net margin of 23.17%.

ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer US Small Cap Cash Cows 100 ETF (CALF), Global X Genomics & Biotechnology ETF (GNOM), ETFMG Treatments Testing and Advancements ETF (GERM), Janus Henderson Small Cap Growth Alpha ETF (JSML) and Invesco S&P SmallCap Health Care ETF (PSCH).

Fulgent Genetics updated its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $56.00 million-$56.00 million, compared to the consensus revenue estimate of $60.92 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.71%), Pacer Advisors Inc. (1.98%), Geode Capital Management LLC (1.34%), JPMorgan Chase & Co. (1.15%), Morgan Stanley (0.90%) and American Century Companies Inc. (0.81%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLGT stock can currently be purchased for approximately $30.15.

Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $890.00 million and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or $4.56 on an earnings per share basis.

The company employs 1,012 workers across the globe.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.